Early-Onset Immune Reconstitution Inflammatory Syndrome After the Initiation of Antiretroviral Therapy in an AIDS-Stage Patient: A Case Report

Jorge L. Vélez-Paez; Christian Castro-Bustamante; Manuel Gallegos-Paredes; Erick Tutin-Miniguano; Hugo A. Tirapé-Castro

doi:10.54034/mic.e2354

Authors

Jorge L. Vélez-Paez Intensive Care Unit, Hospital Provincial Pablo Arturo Suárez, Quito, Ecuador; Universidad Central del Ecuador, Facultad de Ciencias Médicas, Quito, Ecuador; Pontificia Universidad Católica del Ecuador, Posgrado de Medicina Crítica y terapia Intensiva, Quito, Ecuador https://orcid.org/0000-0002-6956-4475
Christian Castro-Bustamante Intensive Care Unit, Hospital Provincial Pablo Arturo Suárez, Quito, Ecuador
Manuel Gallegos-Paredes Intensive Care Unit, Hospital Provincial Pablo Arturo Suárez, Quito, Ecuador; Pontificia Universidad Católica del Ecuador, Posgrado de Medicina Crítica y terapia Intensiva, Quito, Ecuador
Erick Tutin-Miniguano Intensive Care Unit, Hospital Provincial Pablo Arturo Suárez, Quito, Ecuador; Pontificia Universidad Católica del Ecuador, Posgrado de Medicina Crítica y terapia Intensiva, Quito, Ecuador
Hugo A. Tirapé-Castro Intensive Care Unit, Hospital Provincial Pablo Arturo Suárez, Quito, Ecuador; Pontificia Universidad Católica del Ecuador, Posgrado de Medicina Crítica y terapia Intensiva, Quito, Ecuador

DOI:

https://doi.org/10.54034/mic.e2354

Keywords:

HIV, AIDS, immune reconstitution inflammatory syndrome, ART, pneumocystosis, candidiasis

Abstract

Introduction: Immune reconstitution inflammatory syndrome (IRIS) can occur in patients with advanced HIV infection shortly after initiating antiretroviral therapy (ART). Although it usually manifests between 2 and 8 weeks of treatment, earlier presentations have been described, particularly in patients with very low CD4 counts and high viral loads. Case Presentation: A 43-year-old male, with a CD4 count of 10 cells/µL and a viral load of 432,000 copies/mL, was admitted due to respiratory failure secondary to Pneumocystis jirovecii infection and Candida findings in tracheal secretions. ART and trimethoprim-sulfamethoxazole (TMP-SMX) were initiated on day 1, together with high-dose corticosteroids (MEDURI protocol) for severe pneumocystosis. By day 5 of ART, he developed persistent fever (up to 40 °C), leukocytosis, and elevated inflammatory markers, without new microbiological findings despite broad-spectrum antibiotic therapy. A diagnosis of possible IRIS was considered, as the fever did not subside with antimicrobial coverage and other infections were ruled out. Clinical stabilization was achieved around day 20, highlighting the importance of early recognition of IRIS in critically ill AIDS patients. Conclusions: The presence of fever and clinical deterioration in the early stages of ART necessitates ruling out active or persistent infections; however, an inflammatory dysfunction such as IRIS can also occur before 2 weeks of treatment. This case report underscores the need for close surveillance and a multidisciplinary approach to optimize the management of complications in patients with advanced AIDS.

References

1. French MA, Price P, Stone SF. Clinical syndromes of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients. Curr Opin HIV AIDS. 2008;3(4):445-451.

2. Meintjes G, Lynen L. Prevention and treatment of the immune reconstitution inflammatory syndrome. Curr Opin HIV AIDS. 2008;3(4):468-476.

3. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC Jr, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005;19(4):399-406.

4. Lanzafame M, Vento S. IRIS after HAART initiation in HIV-positive patients with AIDS-defining opportunistic infections: from pathogenesis to management. Expert Rev Anti Infect Ther. 2016;14(8):761-777.

5. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Department of Health and Human Services; 2023 [cited 2025 Apr 1]. Available from: https://clinicalinfo.hiv.gov/

6. Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1–infected individuals: proposed clinical case definitions. Lancet Infect Dis. 2010;10(11):791-802.

7. Lawn SD, Bekker LG, Middelkoop K, Myer L, Wood R. Cryptococcal immune reconstitution disease: manifestations and risk factors in South African antiretroviral treatment cohort. AIDS. 2009;23(14):1674-1676.

8. Bloss G, Heiligenstein J, Amara R, Freedberg KA. Immune reconstitution inflammatory syndrome in advanced HIV: pathogenesis, clinical presentation, and management. Infect Dis Clin North Am. 2023;37(3):617-633.

9. Müller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting HAART for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(4):251-261.

10. Barber DL, Andrade BB, Sereti I, Sher A. Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nat Rev Microbiol. 2012;10(2):150–156.

11. Torres RA, Lewis W. Immune reconstitution inflammatory syndrome (IRIS) in AIDS. Ann Intern Med. 2014;161(6):448-456.

12. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8(8):516–523.

13. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Department of Health and Human Services; 2023 [cited 2025 Apr 1]. Available from: https://clinicalinfo.hiv.gov/

14. Karunajeewa H, Freedberg KA, Eholié SP. Early IRIS presentations in AIDS patients with advanced immunosuppression: a cohort study. HIV Med. 2021;22(10):865-873.

15. Freedberg KA, Amara R, Bloss G. Rapid-onset immune reconstitution inflammatory syndrome: systematic review of case reports in severely immunocompromised PLHIV. Lancet HIV. 2022;9(7):e456-e468.